Zhengwei Ma

Zhengwei Ma

Auto-generated profile, based on publicly available information

Zhengwei Ma

Department of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, Georgia, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
ZMZhengwei Ma
Zhengwei Ma
LLLin Li
Lin Li
MLMan Livingston
Man Livingston
DZDongshan Zhang
Dongshan Zhang
QMQing-Sheng Mi
Qing-Sheng Mi
ZDZheng Dong
Zheng Dong
Dysregulation of autophagy in diabetic kidney disease (DKD) has been reported, but the underlying mechanism and its pathogenic role remain elusive. We show that autophagy was inhibited in DKD models and in human diabetic kidneys. Ablation of autophagy-related gene 7 (Atg7) from kidney proximal tubules led to autophagy deficiency and worse renal hypertrophy, tubular damage, inflammation, fibrosis, and albuminuria in diabetic mice, indicating a protective role of autophagy in DKD. Autophagy impairment in DKD was associated with the downregulation of unc-51–like autophagy-activating kinase 1 (ULK1), which was mediated by the upregulation of microRNA-214 (miR-214) in diabetic kidney cells and tissues. Ablation of miR-214 from kidney proximal tubules prevented a decrease in ULK1 expression and autophagy impairment in diabetic kidneys, resulting in less renal hypertrophy and albuminuria. Furthermore, blockade of p53 attenuated miR-214 induction in DKD, leading to higher levels of ULK1 and autophagy, accompanied by an amelioration of DKD. Compared with nondiabetic samples, renal biopsies from patients with diabetes showed induction of p53 and miR-214, associated with downregulation of ULK1 and autophagy. We found a positive correlation between p53/miR-214 and renal fibrosis, but a negative correlation between ULK1/LC3 and renal fibrosis in patients with diabetes. Together, these results identify the p53/miR-214/ULK1 axis in autophagy impairment in diabetic kidneys, pinpointing possible therapeutic targets for DKD.

24 April 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
Siyao LiSiyao Li
Siyao Li
MLMan Livingston
Man Livingston
ZMZhengwei Ma
Zhengwei Ma
XHXiaoru Hu
Xiaoru Hu
LWLu Wen
Lu Wen
ZDZheng Dong
Zheng Dong
Cisplatin is a widely used chemotherapy drug; however, it induces both acute and chronic kidney diseases (CKD) in patients with cancer. The pathogenesis of cisplatin-induced CKD is unclear, and effective renoprotective approaches are not available. Here, we report that repeated low-dose cisplatin (RLDC) treatment of C57BL/6 mice induced chronic cellular senescence in kidney tubules, accompanied with tubular degeneration and profibrotic phenotype transformation that culminated in maladaptive repair and renal fibrosis. Suppression of tubular senescence by senolytic drugs ABT-263 and Fisetin attenuated renal fibrosis and improved tubular repair, as indicated by restoration of tubular regeneration and renal function. In vitro, RLDC also induced senescence in mouse proximal tubular (BUMPT) cells. ABT-263 eliminated senescent BUMPT cells following RLDC treatment, reversed the profibrotic phenotype of the cells, and increased their clonogenic activity. Moreover, ABT-263 alleviated the paracrine effect of RLDC-treated BUMPT cells on fibroblasts for fibrosis. Consistently, knockdown of p16 suppressed post-RLDC senescence and fibrotic changes in BUMPT cells and alleviated their paracrine effects on renal fibroblast proliferation. These results indicate that persistent induction of tubular senescence plays an important role in promoting cisplatin-induced CKD. Targeting senescent tubular cells may be efficient for improvement of kidney repair and for the prevention and treatment of cisplatin-induced CKD.

10 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
XHxiaoru hu
xiaoru hu
ZMZhengwei Ma
Zhengwei Ma
LWLu Wen
Lu Wen
Siyao LiSiyao Li
Siyao Li
ZDZheng Dong
Zheng Dong
Cisplatin is a widely used chemotherapeutic agent but its clinical use is often limited by nephrotoxicity. Autophagy is a lysosomal degradation pathway that removes protein aggregates and damaged or dysfunctional cellular organelles for maintaining cell homeostasis. Upon cisplatin exposure, autophagy is rapidly activated in renal tubule cells to protect against acute cisplatin nephrotoxicity. Mechanistically, the protective effect is mainly related to the clearance of damaged mitochondria via mitophagy. The role and regulation of autophagy in chronic kidney problems after cisplatin treatment are currently unclear, despite the significance of research in this area. In cancers, autophagy may prevent tumorigenesis, but autophagy may reduce the efficacy of chemotherapy by protecting cancer cells. Future research should focus on developing drugs that enhance the anti-tumor effects of cisplatin while protecting kidneys during cisplatin chemotherapy.

31 January 2022 in The American Journal of Pathology
Verified
Journal Article
Closed access
ZMZhengwei Ma
Zhengwei Ma
XHXiaoru Hu
Xiaoru Hu
Hanfei DingHanfei Ding
Hanfei Ding
MZMing Zhang
Ming Zhang
YHYuqing Huo
Yuqing Huo
ZDZheng Dong
Zheng Dong

17 February 2022 in Cells
Verified
Journal Article
Open access
PDF file
SFShuangshuang Fu
Shuangshuang Fu
XHXiaoru Hu
Xiaoru Hu
ZMZhengwei Ma
Zhengwei Ma
QWQingqing Wei
Qingqing Wei
XXXiaohong Xiang
Xiaohong Xiang
ZDZheng Dong
Zheng Dong
Nephrotoxicity is a major side-effect of cisplatin in chemotherapy, which can occur acutely or progress into chronic kidney disease (CKD). The protein p53 plays an important role in acute kidney injury induced by cisplatin, but its involvement in CKD following cisplatin exposure is unclear. Here, we address this question by using experimental models of repeated low-dose cisplatin (RLDC) treatment. In mouse proximal tubular BUMPT cells, RLDC treatment induced p53 activation, apoptosis, and fibrotic changes, which were suppressed by pifithrin-α, a pharmacologic inhibitor of p53. In vivo, chronic kidney problems following RLDC treatment were ameliorated in proximal tubule-specific p53-knockout mice (PT-p53-KO mice). Compared with wild-type littermates, PT-p53-KO mice showed less renal damage (KIM-1 positive area: 0.97% vs. 2.5%), less tubular degeneration (LTL positive area: 15.97% vs. 10.54%), and increased proliferation (Ki67 positive area: 2.42% vs. 0.45%), resulting in better renal function after RLDC treatment. Together, these results indicate that p53 in proximal tubular cells contributes significantly to the development of chronic kidney problems following cisplatin chemotherapy.

10 January 2023 in Laboratory Investigation
Verified
Journal Article
Closed access
XHXiaoru Hu
Xiaoru Hu
ZMZhengwei Ma
Zhengwei Ma
SLSiyao Li
Siyao Li
LWLu Wen
Lu Wen
YHYuqing Huo
Yuqing Huo
ZDZheng Dong
Zheng Dong